We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Critical Gene Altered in Numerous Fibroadenoma Patients

By LabMedica International staff writers
Posted on 13 Aug 2014
Advanced DNA sequencing technologies have been used to identify a critical gene that was repeatedly disrupted in nearly 60% of fibroadenoma cases.

Frequently discovered in clinical workups for breast cancer diagnosis and during routine breast cancer screening, clinicians often face the challenge of distinguishing fibroadenomas from breast cancer.

A multidisciplinary team of scientists from the National Cancer Center Singapore (Singapore) and their colleagues studies a total of 98 fibroadenoma tumors of which 12 were from fresh-frozen tumors and a further 86 were from archival formalin-fixed paraffin-embedded (FFPE) samples. More...
Tumors and whole blood were obtained from patients undergoing surgical excision of fibroadenoma.

The team used a variety of molecular techniques including a technique called laser capture microdissection (LCM). Fresh-frozen fibroadenomas were embedded in optimal cutting temperature (OCT) compound and 8 μm-thick sections were cut using a microtome cryostat. Stained slides were then loaded onto the laser capture microscope stage. The ArcturusXT Laser Capture Microdissection (LCM) System and a Capsure Macro LCM cap (Life Technologies, Grand Island, NY, USA) were then placed automatically over the chosen area of the tissue.

By analyzing all the protein-coding genes in a panel of fibroadenomas from the patients, the team identified frequent mutations in a gene called Mediator Complex Subunit 12 (MED12) in a remarkable 60% of fibroadenomas. Like most breast tumors including breast cancers, fibroadenomas consist of a mixed population of different cell types, called epithelial cells and stromal cells. However, unlike breast cancers where the genetic abnormalities arise from the epithelial cells, the scientists showed that the pivotal MED12 mutations in fibroadenomas are found in the stromal cells using the LCM technique.

Patrick Tan, MD, PhD, a professor and a lead author of the study said, “It is amazing that these common breast tumors can be caused by such a precise disruption in a single gene. Our findings show that even common diseases can have a very exact genetic basis. Importantly, now that we know the cause of fibroadenoma, this study can have many potential applications. For example, measuring the MED12 gene in breast lumps may help clinicians to distinguish fibroadenomas from other types of breast cancer. Drugs targeting the MED12 pathway may also be useful in patients with multiple and recurrent fibroadenomas as this could help patients avoid surgery and relieve anxiety.” The study was published on July 20, 2014, in the journal Nature Genetics.

Related Links:

National Cancer Center Singapore
Life Technologies, Grand Island



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.